HTG

Transcriptome-Informed

AI-Powered

Patient-Focused
"HTG technology allowed us to take our research further faster."

Dr. Peter Ansell

Scientific Director and Research Fellow

Precision Medicine-Oncology

AbbVie

Read more
“ Given our excellent experience with the HTG EdgeSeq platform for Gene Expression Profiling in FFPE samples we were confident using this process with scarce lung-draining lymph node tissue from lethal COVID-19 cases collected at autopsy, leading to a successful study and novel insights.”

Prof. Alexandar Tzankov

BRCCH Principal Investigator, University Hospital Basel
Learn More

Profiling

Life science tools and diagnostics based on proprietary transcriptomic technologies and informatics.

Therapeutics

Transcriptome-informed and AI-powered drug discovery and design

Peter Ansell, Ph.D., Scientific Director and Research Fellow, Precision Medicine Oncology at AbbVie discussed how his team overcame many challenges they have previously faced using FFPE clinical samples by integrating HTG’s innovative HTG Transcriptome Panel (HTP) into their biomarker strategies.

Stream on-demand webinar

News & Events

HTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Convention

TUCSON, Ariz. , May 18, 2023 (GLOBE NEWSWIRE) - HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023…

Category:
Press Releases

Keep Reading

HTG Highlights the Advantages of Its Drug Discovery Engine

TUCSON, Ariz. , May 16, 2023 (GLOBE NEWSWIRE) - HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business….

Category:
Press Releases

Keep Reading

HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlights

TUCSON, Ariz. , May 10, 2023 (GLOBE NEWSWIRE) - HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights….